Breast Cancer Regimen Is Dose Dense, Dose Intense

Oncology NEWS InternationalOncology NEWS International Vol 13 No 8
Volume 13
Issue 8

NEW ORLEANS-A German study has provided more support for a dose-dense chemotherapy approach as adjuvant therapy for high-risk breast cancer. The investigators found improvements in

 NEW ORLEANS—A German study has provided more support for a dose-dense chemotherapy approach as adjuvant therapy for high-risk breast cancer. The investigators found improvements in disease-free and overall survival with sequential dose-dense therapy, compared with conventionally scheduled sequential chemotherapy. Speaking at the 40th Annual Meeting of the American Society of Clinical Oncology (abstract 513), Volker J. Möbus, MD, of Staedtisches Klinikum, Frankfurt, reported 28-month interim results from the multi-center phase III trial of the German AGO (Arbeitsgemeinschaft fuer Gynaekologische Onkologie) group. Dr. Möbus called the experimental regimen "dose intense" as well as "dose dense," as the individual doses were intensified and the drugs were given more frequently.

The study randomized 1,284 patients age 65 or less with four or more positive nodes to receive standard therapy with four courses of epirubicin (Ellence) (90 mg/m2) and cyclophosphamide (600 mg/m2), followed by four courses of paclitaxel (175 mg/m2) (EC→T) every 3 weeks—or to three courses of sequential dose-dense/dose-intense chemotherapy using higher doses of epirubicin (150 mg/m2), paclitaxel (225 mg/m2), and cyclophosphamide (2,500 mg/m2) (ETC) every 2 weeks with G-CSF (Neupogen) support. Additional randomization in the dose-dense, dose-intense arm also evaluated patients with and without epoetin alfa support (Epogen, Procrit).

At a median follow-up of 28 months, with data available on 1,169 patients, significantly fewer patients in the sequential dose-dense arm had relapsed: 94 vs 127 with conventional therapy (P = .0009), for a relative risk reduction of 36%. For patients with 10 or more positive nodes, the relative risk reduction for relapse was 50%. The difference in relapse-free survival was highly significant, resulting in an estimated 3-year survival of 80% with dose-dense therapy vs 70% with standard therapy (P = .00009).

Mortality Rates

Mortality rates also favored the dose-dense arm, with 43 deaths with the dose-dense approach vs 60 with conventional therapy (P = .03), yielding an estimated 3-year overall survival of 90% vs 87%, respectively, Dr. Möbus reported.

The results appear to support those of the previous CALGB 9741 study, which showed a benefit for a dose-dense (every 2 week) schedule of doxorubicin/paclitaxel/cyclophosphamide, compared with a conventional every-3-week regimen in women with node-positive stage II/IIIa breast cancer. The new study, Dr. Möbus said, provides positive data from a second trial, thus potentially swaying oncologists to begin using the dose-dense regimen in their own practices.

Use of epoetin alfa improved tolerability of the dose-dense regimen, and there were no differences in relapse-free or overall survival between the dose-dense patients receiving and not receiving epoetin alfa. While red blood cell transfusions were necessary in 28% of the overall experimental arm, they were reduced to 12% in the group randomized to receive epoetin alfa (P = .0001). "There was a preventive effect of epoetin alfa for anemia," he said.

Hematological toxicity was more frequent in the dose-dense arm, with the highest incidence seen during treatment with cyclophosphamide and lowest with paclitaxel. Febrile neutropenia requiring hospitalization occurred in 7% with dose-dense therapy vs 2% with conventional therapy. There were no treatment-related deaths during therapy.


Discussant Antonio C. Wolff, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Center, commented: "This was a large study with promising interim data, but if confirmed, I’m not sure exactly what worked. Was it the frequency of the schedule, the intensification of individual doses, or both? And if this trial recapitulates CALGB 9741, which demonstrated value in densification without escalation, is dose intensification in addition to dose densification needed, and are there concerns about long-term toxicities?"

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content